A cell-based high-content screening assay reveals activators and inhibitors of cancer cell invasion

Science Signaling

Volumn 4, Issue 183, 2011, Pages

  Quintavalle, Manuela ^a   Elia, Leonardo ^b,c   Price, Jeffrey H ^a,d   Heynen Genel, Susanne ^a   Courtneidge, Sara A ^a  

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c IRCCS MULTIMEDICA   (Italy)

^d VALA SCIENCES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; 7 CYCLOPENTYL 5 (4 PHENOXY)PHENYL 7H PYRROLO[2,3 DEXTRO]PYRIMIDIN 4 YLAMINE; CALDESMON; CANTHARIDIN; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE INHIBITOR; GCP 74514 A; GCP 74514A; PACLITAXEL; PURVALANOL A; PYRIMIDINE; UNCLASSIFIED DRUG; UO 126; ANTINEOPLASTIC AGENT; CALMODULIN BINDING PROTEIN; PRIMER DNA;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CELL INVASION; CANCER INVASION; CANCER RESISTANCE; CANCER SCREENING; CELL INVASION; CONTROLLED STUDY; HIGH CONTENT SCREENING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; ANALYSIS OF VARIANCE; ANIMAL; CELL STRAIN 3T3; CELL SURFACE; DRUG EFFECT; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; PATHOPHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE;

ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC AGENTS; CALMODULIN-BINDING PROTEINS; CELL LINE, TUMOR; CELL SURFACE EXTENSIONS; CYCLIN-DEPENDENT KINASE 5; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; DNA PRIMERS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MICE; NEOPLASM INVASIVENESS; NIH 3T3 CELLS; PACLITAXEL; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

EID: 79960779358     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2002032     Document Type: Article

References (49)

1. C. L. Chaffer, R. A. Weinberg, A perspective on cancer cell metastasis. Science 331, 1559-1564 (2011).
2. D. Hanahan, R. A. Weinberg, The hallmarks of cancer. Cell 100, 57-70 (2000).
3. D. F. Seals, E. F. Azucena Jr., I. Pass, L. Tesfay, R. Gordon, M. Woodrow, J. H. Resau, S. A. Courtneidge, The adaptor protein Tks5/Fish is required for podosome formation and function, and for the protease-driven invasion of cancer cells. Cancer Cell 7, 155-165 (2005).
4. M. Gimona, R. Buccione, S. A. Courtneidge, S. Linder, Assembly and biological role of podosomes and invadopodia. Curr. Opin. Cell Biol. 20, 235-241 (2008).
5. E. S. Clark, B. Brown, A. S. Whigham, A. Kochaishvili, W. G. Yarbrough, A. M. Weaver, Aggressiveness of HNSCC tumors depends on expression levels of cortactin, a gene in the 11q13 amplicon. Oncogene 28, 431-444 (2009).
6. A. M. Weaver, Cortactin in tumor invasiveness. Cancer Lett. 265, 157-166 (2008).
7. B. Blouw,D.F.Seals, I.Pass, B.Diaz,S.A.Courtneidge,Arole for the podosome/invadopodia scaffold protein Tks5 in tumor growth in vivo. Eur. J. Cell Biol. 87, 555-567 (2008).
8. G. Tarone, D. Cirillo, F. G. Giancotti, P. M. Comoglio, P. C. Marchisio, Rous sarcoma virus-transformed fibroblasts adhere primarily at discrete protrusions of the ventral membrane called podosomes. Exp. Cell Res. 159, 141-157 (1985).
9. W. T. Chen, Proteolytic activity of specialized surface protrusions formed at rosette contact sites of transformed cells. J. Exp. Zool. 251, 167-185 (1989).
10. M. Quintavalle, L. Elia, G. Condorelli, S. A. Courtneidge, MicroRNA control of podosome formation in vascular smooth muscle cells in vivo and in vitro. J. CellBiol. 189, 13-22 (2010).
11. J. H. Zhang, T. D. Chung, K. R. Oldenburg, A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4, 67-73 (1999).
12. H. Devalapally, Z. Duan, M. V. Seiden, M. M. Amiji, Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. Clin. Cancer Res. 14, 3193-3203 (2008).
13. R. Dhavan, L. H. Tsai, A decade of CDK5. Nat. Rev. Mol. Cell Biol. 2, 749-759 (2001).
14. N. S. Gray, L. Wodicka, A. M. Thunnissen, T. C. Norman, S. Kwon, F. H. Espinoza, D. O. Morgan, G. Barnes, S. LeClerc, L. Meijer, S. H. Kim, D. J. Lockhart, P. G. Schultz, Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281, 533-538 (1998).
15. H. Lin, M. C. Chen, C. Y. Chiu, Y. M. Song, S. Y. Lin, Cdk5 regulates STAT3 activation and cell proliferation in medullary thyroid carcinoma cells. J. Biol. Chem. 282, 2776-2784 (2007).
16. Z. Songyang, K. P. Lu, Y. T. Kwon, L. H. Tsai, O. Filhol, C. Cochet, D. A. Brickey, T. R. Soderling, C. Bartleson, D. J. Graves, A. J. DeMaggio, M. F. Hoekstra, J. Blenis, T. Hunter, L. C. Cantley, A structural basis for substrate specificities of protein Ser/Thr kinases: Primary sequence preference of casein kinases I and II, NIMA, phosphorylase kinase, calmodulin-dependent kinase II, CDK5, and Erk1. Mol. Cell. Biol. 16, 6486-6493 (1996).
17. R. Eves, B. A. Webb, S. Zhou, A. S. Mak, Caldesmon is an integral component of podosomes in smooth muscle cells. J. Cell Sci. 119, 1691-1702 (2006).
18. T. Yoshio, T. Morita, Y. Kimura, M. Tsujii, N. Hayashi, K. Sobue, Caldesmon suppresses cancer cell invasion by regulating podosome/invadopodium formation. FEBS Lett. 581, 3777-3782 (2007).
19. Y. M. Li, J. E. Casida, Cantharidin-binding protein: Identification as protein phosphatase 2A. Proc. Natl. Acad. Sci. U.S.A. 89, 11867-11870 (1992).
20. R. E. Honkanen, Cantharidin, another natural toxin that inhibits the activity of serine/ threonine protein phosphatases types 1 and 2A. FEBS Lett. 330, 283-286 (1993).
21. C. Letourneux, G. Rocher, F. Porteu, B56-containing PP2A dephosphorylate ERK and their activity is controlled by the early gene IEX-1 and ERK. EMBO J. 25, 727-738 (2006).
22. W. Tsauer, J. G. Lin, P. Y. Lin, F. L. Hsu, H. C. Chiang, The effects of cantharidin analogues on xanthine oxidase. Anticancer Res. 17, 2095-2098 (1997).
23. B. Diaz, G. Shani, I. Pass, D. Anderson,M. Quintavalle, S. A. Courtneidge, Tks5-dependent, Nox-mediated generation of reactive oxygen species is necessary for invadopodia formation. Sci. Signal. 2, ra53 (2009).
24. B. R. Goldspiel, Clinical overview of the taxanes. Pharmacotherapy 17, 110S-125S (1997).
25. M. A. Jordan, L. Wilson, Microtubules and actin filaments: Dynamic targets for cancer chemotherapy. Curr. Opin. Cell Biol. 10, 123-130 (1998).
26. P. B. Schiff, J. Fant, S. B. Horwitz, Promotion of microtubule assembly in vitro by taxol. Nature 277, 665-667 (1979).
27. S. Linder, K. Hufner, U. Wintergerst, M. Aepfelbacher, Microtubule-dependent formation of podosomal adhesion structures in primary human macrophages. J. Cell Sci. 113 (Pt. 23), 4165-4176 (2000).
28. M. Schoumacher, R. D. Goldman, D. Louvard, D. M. Vignjevic, Actin, microtubules, and vimentin intermediate filaments cooperate for elongation of invadopodia. J. Cell Biol. 189, 541-556 (2010).
29. J. M. Yang, G. Y. Yang, D. J. Medina, A. D. Vassil, J. Liao, W. N. Hait, Treatment of multidrug resistant (MDR1) murine leukemia with P-glycoprotein substrates accelerates the course of the disease. Biochem. Biophys. Res. Commun. 266, 167-173 (1999).
30. O. Camara, M. Rengsberger, A. Egbe, A. Koch, M. Gajda, U. Hammer, C. Jorke, C. Rabenstein, M. Untch, K. Pachmann, The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer. Ann. Oncol. 18, 1484-1492 (2007).
31. H. Kajiyama, K. Shibata, M. Terauchi, M. Yamashita, K. Ino, A. Nawa, F. Kikkawa, Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int. J. Oncol. 31, 277-283 (2007).
32. R. Suryadinata, M. Sadowski, B. Sarcevic, Control of cell cycle progression by phosphorylation of cyclin-dependent kinase (CDK) substrates. Biosci. Rep. 30, 243-255 (2010).
33. F. Chen, G. P. Studzinski, Expression of the neuronal cyclin-dependent kinase 5 activator p35Nck5a in human monocytic cells is associated with differentiation. Blood 97, 3763-3767 (2001).
34. J. B. Lazaro, M. Kitzmann, M. A. Poul, M. Vandromme, N. J. Lamb, A. Fernandez, Cyclin dependent kinase 5, cdk5, is a positive regulator of myogenesis inmouseC2 cells. J. Cell Sci. 110 (Pt 10), 1251-1260 (1997).
35. C. J. Strock, J. I. Park, E. K. Nakakura, G. S. Bova, J. T. Isaacs, D. W. Ball, B. D. Nelkin, Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. Cancer Res. 66, 7509-7515 (2006).
36. R. Liu, B. Tian, M. Gearing, S. Hunter, K. Ye, Z. Mao, Cdk5-mediated regulation of the PIKE-A-Akt pathway and glioblastoma cell invasion. Proc. Natl. Acad. Sci. U.S.A. 105, 7570-7575 (2008).
37. C. Huang, Z. Rajfur, N. Yousefi, Z. Chen, K. Jacobson, M. H. Ginsberg, Talin phosphorylation by Cdk5 regulates Smurf1-mediated talin head ubiquitylation and cell migration. Nat. Cell Biol. 11, 624-630 (2009).
38. P. C. Marchisio, L. Bergui, G. C. Corbascio, O. Cremona, N. D'Urso, M. Schena, L. Tesio, F. Caligaris-Cappio, Vinculin, talin, and integrins are localized at specific adhesion sites of malignant B lymphocytes. Blood 72, 830-833 (1988).
39. M. A. McNiven, M. Baldassarre, R. Buccione, The role of dynamin in the assembly and function of podosomes and invadopodia. Front. Biosci. 9, 1944-1953 (2004).
40. H. M. Kocher, J. Sandle, T. A. Mirza, N. F. Li, I. R. Hart, Ezrin interacts with cortactin to form podosomal rosettes in pancreatic cancer cells. Gut 58, 271-284 (2009).
41. H. S. Yang, P. W. Hinds, Increased ezrin expression and activation by CDK5 coincident with acquisition of the senescent phenotype. Mol. Cell 11, 1163-1176 (2003).
42. K. Tomizawa, S. Sunada, Y. F. Lu, Y. Oda, M. Kinuta, T. Ohshima, T. Saito, F. Y. Wei, M. Matsushita, S. T. Li, K. Tsutsui, S. Hisanaga, K. Mikoshiba, K. Takei, H. Matsui, Cophosphorylation of amphiphysin I and dynamin I by Cdk5 regulates clathrin-mediated endocytosis of synaptic vesicles. J. Cell Biol. 163, 813-824 (2003).
43. C. L. Wang, Caldesmon and smooth-muscle regulation. Cell Biochem. Biophys. 35, 275-288 (2001).
44. R. Dabrowska, N. Kulikova, M. Gagola, Nonmuscle caldesmon: Its distribution and involvement in various cellular processes. Review article. Protoplasma 224, 1-13 (2004).
45. Y. Li, J. L. Lin, R. S. Reiter, K. Daniels, D. R. Soll, J. J. Lin, Caldesmon mutant defective in Ca2+-calmodulin binding interferes with assembly of stress fibers and affects cell morphology, growth and motility. J. Cell Sci. 117, 3593-3604 (2004).
46. J. Tanaka, T. Watanabe, N. Nakamura, K. Sobue, Morphological and biochemical analyses of contractile proteins (actin, myosin, caldesmon and tropomyosin) in normal and transformed cells. J. Cell Sci. 104 (Pt 2), 595-606 (1993).
47. T. Mirzapoiazova, I. A. Kolosova, L. Romer, J. G. Garcia, A. D. Verin, The role of caldesmon in the regulation of endothelial cytoskeleton and migration. J. Cell. Physiol. 203, 520-528 (2005).
48. S. Yamashiro, Y. Yamakita, K. Yoshida, K. Takiguchi, F. Matsumura, Characterization of the COOH terminus of non-muscle caldesmon mutants lacking mitosis-specific phosphorylation sites. J. Biol. Chem. 270, 4023-4030 (1995).
49. J. C. Hedges, B. C. Oxhorn, M. Carty, L. P. Adam, I. A. Yamboliev, W. T. Gerthoffer, Phosphorylation of caldesmon by ERK MAP kinases in smooth muscle. Am. J. Physiol. Cell Physiol. 278, C718-C726 (2000).